Pembrolizumab biosimilar (Sun Pharmaceutical)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NamePembrolizumab biosimilar (Sun Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionImmunostimulantsProgrammed cell death protein 1 blockersApoptosis stimulants +[4] 
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSun Pharmaceutical Industries Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSun Pharmaceutical Industries Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A